文献速递脑血管病

自动化软件系统促进抗凝并降低卒中风险:整群随机对照试验

Automated Software System to Promote Anticoagulation and Reduce Stroke Risk: Cluster-Randomized Controlled Trial.
PubMed 文献 · Stroke · 2017-01-24

该整群随机对照试验评估自动化软件工具AURAS-AF在常规诊疗中识别房颤未抗凝患者的效果。干预组短暂性脑缺血发作记录发生率更高,12个月时全因卒中和出血发生率有降低趋势但未达显著。

要点

  • 自动化提醒未显著提高6个月时口服抗凝药处方比例。
  • 干预组短暂性脑缺血发作记录发生率更高,可能为检出改善或过度诊断。
  • 12个月时全因卒中和出血发生率有降低趋势,但差异未达统计学显著。

核心结论

  • AURAS-AF软件未显著改变口服抗凝药处方比例。
  • 短暂性脑缺血发作诊断率增加与12个月卒中和出血减少相关,但后者仅为边缘显著性。

研究设计与样本

  • 干预组在获取合格患者电子健康记录时显示筛查提醒,直至做出抗凝治疗决策;对照组继续常规诊疗。

主要发现

  • 6个月时口服抗凝药处方平均比例:干预组66.3%(SD=9.3),对照组63.9%(SD=9.5),校正差异1.21%(95%CI -0.72至3.13)。
  • 记录到的短暂性脑缺血发作发生率干预组更高(中位数每1000名房颤患者10.0 vs 2.3,P=0.027)。
  • 12个月时全因卒中发生率降低(P=0.06),出血发生率降低(P=0.054)。
  • 未报告软件对临床决策的不良影响。

临床怎么用

  • 该软件提醒未能显著改善抗凝处方,临床不宜仅依赖此类自动化提醒提高抗凝率。
  • 软件可能增加短暂性脑缺血发作的诊断,需关注过度诊断风险。

局限性

  • 原文未明确报告样本量、随访细节及盲法情况。
  • 短暂性脑缺血发作诊断增加可能源于检出改善或过度诊断,机制不明确。
  • 卒中和出血的降低仅为边缘显著性,需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Oral anticoagulants (OAC) substantially reduce risk of stroke in atrial fibrillation, but uptake is suboptimal. Electronic health records enable automated identification of people at risk but not receiving treatment. We investigated the effectiveness of a software tool (AURAS-AF [Automated Risk Assessment for Stroke in Atrial Fibrillation]) designed to identify such individuals during routine care through a cluster-randomized trial. METHODS: Screen reminders appeared each time the electronic health records of an eligible patient was accessed until a decision had been taken over OAC treatment. Where OAC was not started, clinicians were prompted to indicate a reason. Control practices continued usual care. The primary outcome was the proportion of eligible individuals receiving OAC at 6 months. Secondary outcomes included rates of cardiovascular events and reports of adverse effects of the software on clinical decision-making. RESULTS: Forty-seven practices were randomized. The mean proportion-prescribed OAC at 6 months was 66.3% (SD=9.3) in the intervention arm and 63.9% (9.5) in the control arm (adjusted difference 1.21% [95% confidence interval -0.72 to 3.13]). Incidence of recorded transient ischemic attack was higher in the intervention practices (median 10.0 versus 2.3 per 1000 patients with atrial fibrillation; P=0.027), but at 12 months, we found a lower incidence of both all cause stroke (P=0.06) and hemorrhage (P=0.054). No adverse effects of the software were reported. CONCLUSIONS: No significant change in OAC prescribing occurred. A greater rate of diagnosis of transient ischemic attack (possibly because of improved detection or overdiagnosis) was associated with a reduction (of borderline significance) in stroke and hemorrhage over 12 months. CLINICAL TRIAL REGISTRATION: URL: http://www.isrctn.com. Unique Identifier: ISRCTN55722437.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Holt TA, Dalton A, Marshall T, et al. Automated Software System to Promote Anticoagulation and Reduce Stroke Risk: Cluster-Randomized Controlled Trial. Stroke. 2017. PMID: 28119433. doi:10.1161/STROKEAHA.116.015468

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。